Company Overview and News


Add VRX
to your dashboard

Headline News

Valeant Closes Senior Note Offering, Reprices Term Loan

13h zacks
Valeant Pharmaceuticals International, Inc. (VRX - Free Report) closed its previously announced offering of $750,000,000 aggregate principal amount of 5.500% senior secured notes due 2025. (236-0)

Earn A 7% Yield From 2022 Term Closed-End Fund

2017-11-21 seekingalpha
FIV is a closed-end fund that invests in a portfolio of primarily senior secured loans, with 128 different issuers. (165-2)

Can Valeant (VRX) Turn Around on Rebuilding Initiatives?

2017-11-21 zacks
Shares of Valeant Pharmaceuticals International Inc. (VRX - Free Report) have rallied 7.2% year to date compared with the industry’s gain of 2.4%. (242-2)

Red Flags, Portfolio Protection And Short Selling From The Perspective Of A Bull Investor At Heart

2017-11-21 seekingalpha
Long investors can use their own research skills and apply them to both portfolio protection and short investing when supported by the discovery of red flags. (67-1)

TSX makes meagre gain, as energy and gold sectors weigh

2017-11-20 ctvnews.ca
A man watches the financial numbers at the TMX Group in Toronto's financial district, May 9, 2014. (Darren Calabrese/The Canadian Press) (27-0)

Tracking Jeffrey Ubben's ValueAct Portfolio - Q3 2017 Update

2017-11-20 seekingalpha
The top three positions are Twenty First Century Fox, Alliance Data Systems, and Baker Hughes and they add up to ~38% of the portfolio. (288-1)

Tracking John Paulson's Paulson & Company Portfolio - Q3 2017 Update

2017-11-18 seekingalpha
Paulson & Company's largest three positions are the SPDR Gold ETF, Shire plc, and Mylan NV. (1155-10)

Tracking George Soros's Portfolio - Q3 2017 Update

2017-11-17 seekingalpha
Soros's 13F portfolio value decreased from $5.62B to $4.20B this quarter. The number of positions increased from 203 to 227. (866-13)

A Primer On How To Define And Fulfill The Fiduciary Duty Of Care

2017-11-16 seekingalpha
While plenty of attention has been paid to fulfilling the Duty of Loyalty, there is no official guidance on how to fulfill the Duty of Care. (1-0)

Despite Valeant Improvement, VRX Stock Price Is Still Too High

2017-11-15 investorplace
Give credit where credit is due. New CEO Joe Papa has done a nice job in his efforts to turn around Valeant Pharmaceuticals Intl Inc (NYSE:VRX). So far, it hasn’t done much for the VRX stock price, which is basically flat so far in 2017. But flat performance in this market actually isn’t that bad. (324-0)

Valeant (VRX) Announces Pricing of Senior Secured Notes

2017-11-15 zacks
Valeant Pharmaceuticals International, Inc. (VRX - Free Report) announced that it has priced its previously announced offering of $750,000,000 aggregate principal amount of 5.500% senior secured notes due 2025. These will be additional notes and form part of the same series as the existing 5.500% senior secured notes due 2025.Valeant will sell the notes at a price of 100.0% of the principal amount thereof plus accrued interest from Oct 17, 2017. (201-0)

Bill Ackman sticks with his infamous bet against Herbalife

2017-11-13 cnbc
Pershing Square Capital's Bill Ackman revealed a new strategy on Wednesday in his years-long bearish position on Herbalife. (39-1)

Week In Review: China's Creat To Restructure $1.5 Billion Biotest Takeover

2017-11-12 seekingalpha
Creat Group of China has withdrawn its current $1.5 billion offer to acquire Biotest (DE: BIOG) (OTC:BTTAY), a German blood plasma products corporation, because US regulators refused to approve the deal. According to Bloomberg, the Committee on Foreign Investment in the United States was worried that a China corporation would have access to US donor information. Creat and Biotest said the acquisition cannot be completed under the current structure, but the two companies hope to forge a new agreement that will satisfy US regulators. (166-1)

A Primer On How To Define And Fulfill The Fiduciary Duty Of Care

2017-11-11 valuewalk
Some sort of fiduciary rule is coming. Whether it comes from the Department of Labor, the SEC, the CFP Board or individual state regulators, advisors need to be prepared to show they are unequivocally acting in the best interests of clients. (1-0)

BRIEF-Valeant completes sale of Obagi Medical products business to Haitong International Zhongua Finance Acquisition Fund I, L.P.

2017-11-10 reuters
* Valeant Pharmaceuticals completes sale of Obagi Medical products business to Haitong International Zhongua Finance Acquisition Fund I, L.P. Source text for Eikon: Further company coverage: (1-0)

Stock Research Report

Valeant Pharmaceuticals International, Inc. is a multinational, specialty pharmaceutical and medical device company that develops, manufactures, and markets a broad range of branded, generic and branded generic pharmaceuticals, over-the-counter (“OTC”) products and medical devices (contact lenses, intraocular lenses, ophthalmic surgical equipment, and aesthetics devices), which are marketed directly or indirectly in over 100 countries. We are diverse not only in our sources of revenue from our broad drug and medical device portfolio, but also among the therapeutic classes and geographies we serve. We generated revenues of $4,342 million and $4,792 million for the six months ended June 30, 2017 and 2016, respectively. Our portfolio of products falls into three reportable segments: (i) Bausch + Lomb/International, (ii) Branded Rx and (iii) U.S. Diversified Products.

  • The Bausch + Lomb/International segment consists of: (i) sales in the U.S. of pharmaceutical products, OTC products a...
Click for full article